Minirin (Desmopressin Acetate)

Desmopressin acetate mimics the natural hormone vasopressin. It selectively activates V2 receptors in the kidney’s collecting ducts, prompting insertion of water channels that reabsorb water and concentrate urine. It also stimulates endothelial cells to release factor VIII and von Willebrand factor, supporting blood clot formation.

The appropriate dose of Minirin is determined by the prescribing clinician based on the patient’s specific condition, age, renal function and response to therapy. Dosage may vary for diabetes insipidus, nocturnal enuresis, or bleeding disorders, and should follow the healthcare professional’s instructions.

Safety data for desmopressin acetate in pregnancy and lactation are limited, and the product’s pregnancy category is listed as unknown. Clinicians should weigh potential benefits against risks and consider alternative therapies when treating pregnant or nursing individuals.

To request Minirin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with older antidiuretic agents such as vasopressin, desmopressin acetate has a longer half‑life, greater selectivity for V2 receptors, and a reduced risk of vasoconstriction. This makes it especially useful for chronic conditions like diabetes insipidus and for haemostatic purposes, while still requiring careful monitoring of fluid balance.

Minirin nasal spray should be stored at room temperature, ideally below 25 °C. Keep the bottle in its original packaging, protect it from moisture and direct sunlight, and ensure the cap is tightly closed to maintain potency.

Minirin is supplied as a metered‑dose nasal spray. The patient sprays the prescribed number of actuations into each nostril, typically after measuring the dose with the device’s indicator. Administration technique and timing should follow the prescriber’s guidance to achieve optimal effect.

The most serious risks include severe hyponatraemia, which can lead to seizures, coma or hyponatraemic encephalopathy, and rare allergic reactions such as anaphylaxis. Prompt recognition of symptoms like sudden headache, confusion, vomiting or swelling is essential, and medical attention should be sought immediately.

Minirin is contraindicated in patients with known hypersensitivity to desmopressin or any excipients, in those with uncontrolled hypertension, severe renal impairment, or in individuals who are unable to monitor fluid intake and serum sodium. Clinicians should also avoid use in patients taking other potent antidiuretic agents without careful supervision.